Business
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels (<2 mg/L) BGE-102 demonstrated significant reductions in IL-6, a key driver of systemic inflammation and cardiovascular risk, and fibrinogen, an independent predictor of cardiovascular events BGE-102 was well tolerated with a favorabl
About this update from Bioage Labs, Inc.
[{"type":"image","alt":"BioAge Labs, Inc.","displaySize":"","headline":null,"caption":"BioAge Labs, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/612cb01db2ea44f61d54947f4e4723e0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5Q4VL90BcRUw5eG_L017gw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/612cb01db2ea44f61d54947f4e4723e0","width":300,"height":300}},"lazy":false},{"type":"text","content":"First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers","length":162,"tagName":"p"},{"type":"text","content":"BGE-102 achieved 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels (<2 mg/L)","length":115,"tagName":"p"},{"type":"text","content":"BGE-102 demonstrated significant reductions in IL-6, a key driver of systemic inflammation and cardiovascular risk, and fibrinogen, an independent predictor of cardiovascular events","length":181,"tagName":"p"},{"type":"text","content":"BGE-102 was well tolerated with a favorable safety profile","length":58,"tagName":"p"},{"type":"text","content":"Patent issued covering additional composition of matter and novel NLRP3 binding site ","length":84,"tagName":"p"},{"type":"text","content":"Full Phase 1 data, including additional MAD cohorts in obese participants with elevated hsCRP, anticipated 1H 2026; Phase 2a study on track to initiate in 1H 2026","length":162,"tagName":"p"},{"type":"text","content":"EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced additional positive interim data from the ongoing Phase 1 clinical trial evaluating BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor being developed for the treatment of patients with cardiovascular risk factors.","length":541,"tagName":"p"},{"type":"text","content":"In a multiple ascending dose (MAD) cohort of participants with obesity (BMI 32–42) and elevated baseline inflammation (hsCRP >3 mg/L), BGE-102 120 ...